Stock listing
NASDAQ:CLPT ClearPoint Neuro Inc. Stock
Home listing (NASDAQ) of ClearPoint Neuro Inc.
Follow ClearPoint Neuro Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CLPT
$6.91 USD -0.80 (-10.4%)
Close on Nov 20, 2026
- Day range
- $6.85 – $7.45 USDNov 20, 2026
- Volume
- 1.11M sharesNov 20, 2026
- Market cap
- $221.5M USDAt the close on Nov 20, 2026 · price × 32.05M shares outstanding
- 52-week range
- $6.85 – $19.63 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $8.01M USDMedian day 640,195 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CLPT · Home | $6.91 USD | -0.80 (-10.4%) | 1,108,673 | $7.15 | $7.445 | $6.85 | $7.71 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLPT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.91 | -0.80 | -10.4% | $7.15 | $7.445 | $6.85 | 1,108,673 | |
| $7.71 | -0.15 | -1.9% | $7.92 | $8.05 | $7.60 | 638,967 | |
| $7.86 | -0.44 | -5.3% | $8.18 | $8.30 | $7.812 | 640,195 | |
| $8.30 | -0.18 | -2.1% | $8.32 | $8.48 | $8.115 | 973,409 | |
| $8.48 | -0.01 | -0.1% | $8.56 | $8.57 | $8.31 | 505,605 | |
| $8.49 | -0.68 | -7.4% | $8.905 | $9.08 | $8.38 | 703,017 | |
| $9.17 | +0.40 | +4.6% | $8.98 | $9.24 | $8.89 | 440,260 | |
| $8.77 | -0.40 | -4.4% | $8.99 | $9.29 | $8.76 | 425,795 | |
| $9.17 | +0.57 | +6.6% | $8.65 | $9.40 | $8.65 | 479,051 | |
| $8.60 | -0.09 | -1.0% | $8.81 | $8.82 | $8.27 | 945,854 | |
| $8.69 | -1.47 | -14.5% | $10.16 | $10.16 | $8.46 | 1,300,639 | |
| $10.16 | +0.45 | +4.6% | $10.00 | $10.38 | $10.00 | 673,810 | |
| $9.71 | -0.24 | -2.4% | $10.01 | $10.18 | $9.53 | 783,887 | |
| $9.95 | -0.72 | -6.7% | $11.24 | $11.30 | $9.91 | 707,314 | |
| $10.67 | -0.02 | -0.2% | $10.69 | $10.80 | $10.00 | 915,403 | |
| $10.69 | +0.13 | +1.2% | $10.86 | $11.97 | $10.65 | 1,249,798 | |
| $10.56 | +0.87 | +9.0% | $9.59 | $10.75 | $9.58 | 863,762 | |
| $9.69 | +0.65 | +7.2% | $9.05 | $9.77 | $9.00 | 752,938 | |
| $9.04 | -0.10 | -1.1% | $9.17 | $9.17 | $8.91 | 455,576 | |
| $9.14 | -0.11 | -1.2% | $9.19 | $9.22 | $8.95 | 355,472 | |
| $9.25 | 0.00 | 0.0% | $9.30 | $9.43 | $9.06 | 448,647 | |
| $9.25 | -0.20 | -2.1% | $9.47 | $9.58 | $9.22 | 410,531 | |
| $9.45 | +0.28 | +3.1% | $9.27 | $9.72 | $9.192 | 468,179 | |
| $9.17 | +0.10 | +1.1% | $9.11 | $9.22 | $8.95 | 481,029 | |
| $9.07 | -0.57 | -5.9% | $9.58 | $9.60 | $9.00 | 965,000 | |
| $9.64 | +0.40 | +4.3% | $9.11 | $9.68 | $9.10 | 797,600 | |
| $9.24 | -0.57 | -5.8% | $9.68 | $9.80 | $9.19 | 1,012,700 | |
| $9.81 | -0.39 | -3.8% | $10.17 | $10.17 | $9.72 | 792,300 | |
| $10.20 | -0.28 | -2.7% | $10.37 | $10.51 | $10.12 | 397,600 | |
| $10.48 | -0.01 | -0.1% | $10.45 | $10.60 | $10.22 | 409,500 | |
| $10.49 | -0.17 | -1.6% | $10.56 | $10.56 | $10.18 | 717,900 | |
| $10.66 | -0.35 | -3.2% | $10.85 | $10.98 | $10.58 | 490,100 | |
| $11.01 | -0.51 | -4.4% | $11.60 | $11.74 | $10.63 | 903,500 | |
| $11.52 | +0.62 | +5.7% | $10.85 | $11.53 | $10.61 | 760,000 | |
| $10.90 | -0.55 | -4.8% | $11.58 | $11.58 | $10.85 | 831,500 | |
| $11.45 | -0.76 | -6.2% | $12.24 | $12.24 | $11.40 | 765,900 | |
| $12.21 | +0.44 | +3.7% | $11.85 | $12.54 | $11.54 | 1,253,700 | |
| $11.77 | -3.54 | -23.1% | $12.63 | $12.99 | $11.60 | 2,693,800 | |
| $15.31 | +0.48 | +3.2% | $14.64 | $15.42 | $14.24 | 476,200 | |
| $14.83 | +0.22 | +1.5% | $14.77 | $15.12 | $14.36 | 321,300 | |
| $14.61 | -0.36 | -2.4% | $14.82 | $14.90 | $14.23 | 669,800 | |
| $14.97 | -0.82 | -5.2% | $15.55 | $15.83 | $14.53 | 574,000 | |
| $15.79 | +1.82 | +13.0% | $14.00 | $16.49 | $14.00 | 1,142,100 | |
| $13.97 | +0.14 | +1.0% | $13.96 | $14.13 | $13.71 | 373,400 | |
| $13.83 | +0.09 | +0.7% | $13.67 | $13.92 | $13.57 | 525,600 | |
| $13.74 | +0.34 | +2.5% | $13.65 | $13.87 | $13.42 | 477,100 | |
| $13.40 | +0.25 | +1.9% | $13.16 | $13.50 | $13.13 | 382,000 | |
| $13.15 | -0.31 | -2.3% | $13.45 | $13.50 | $12.99 | 642,800 | |
| $13.46 | -0.26 | -1.9% | $13.53 | $13.94 | $13.45 | 478,900 | |
| $13.72 | +0.24 | +1.8% | $13.65 | $13.89 | $13.31 | 1,021,400 | |
| $13.48 | -0.40 | -2.9% | $13.57 | $13.76 | $13.31 | 404,200 | |
| $13.88 | -0.17 | -1.2% | $13.94 | $14.11 | $13.80 | 450,100 | |
| $14.05 | +0.09 | +0.6% | $13.60 | $14.22 | $13.44 | 746,400 | |
| $13.96 | -0.09 | -0.6% | $14.00 | $14.09 | $13.78 | 384,900 | |
| $14.05 | -0.26 | -1.8% | $14.33 | $14.76 | $13.84 | 640,600 | |
| $14.31 | -0.59 | -4.0% | $15.54 | $15.98 | $14.27 | 803,800 | |
| $14.90 | -0.24 | -1.6% | $15.11 | $15.30 | $14.46 | 809,300 | |
| $15.14 | -0.41 | -2.6% | $15.56 | $15.57 | $15.06 | 414,600 | |
| $15.55 | -0.39 | -2.4% | $15.73 | $16.08 | $15.44 | 467,500 | |
| $15.94 | -0.43 | -2.6% | $16.28 | $16.78 | $15.91 | 440,400 | |
| $16.37 | -0.59 | -3.5% | $16.85 | $16.99 | $16.18 | 505,500 | |
| $16.96 | +1.79 | +11.8% | $15.28 | $17.22 | $15.24 | 1,081,430 | |
| $15.17 | -0.22 | -1.4% | $15.40 | $15.44 | $14.65 | 422,072 | |
| $15.39 | +0.20 | +1.3% | $15.13 | $15.53 | $14.97 | 560,500 | |
| $15.19 | -0.77 | -4.8% | $15.77 | $16.08 | $15.18 | 398,100 |
Splits
1 split · NASDAQ:CLPT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-40 | Consolidation |
- Ticker
- NASDAQ:CLPT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 28, 2026
ClearPoint Neuro Reports Third Quarter 2026 Results
Latest earnings call · Oct 28, 2026
ClearPoint Neuro (NASDAQ:CLPT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 28, 2026
Investor Presentation (October 2026)
Investor deck · 26 slides
Latest news
ClearPoint Neuro Reports Third Quarter 2026 Results
Oct 28, 2026
Closed $10.69 (+1.2%) on Oct 29, 2026
ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
Oct 14, 2026
Closed $9.64 (+4.3%) on Oct 15, 2026
Earnings Release Q2 2026
Aug 3, 2026
Closed $12.88 (-16.3%) on Aug 4, 2026
ClearPoint Neuro Reports Second Quarter 2026 Results
Aug 3, 2026
Closed $12.88 (-16.3%) on Aug 4, 2026
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
Jul 31, 2026
Closed $14.94 (+2.5%) on Jul 31, 2026
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
Jul 21, 2026
Closed $15.03 (-2.5%) on Jul 22, 2026
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
May 27, 2026
Closed $11.50 (-2.7%) on May 27, 2026
ClearPoint Neuro Reports First Quarter 2026 Results
May 13, 2026
Closed $12.77 (+4.8%) on May 14, 2026
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
May 13, 2026
Closed $12.77 (+4.8%) on May 14, 2026
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
Apr 29, 2026
Closed $11.18 (+8.1%) on Apr 30, 2026
ClearPoint Neuro Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 16 in the last 12 months · 152 in all · newest Oct 28, 2026 · oldest 2020
- Calls
- 27 calls with a replay · 27 with a transcript · latest Oct 28, 2026
- Decks
- 61 decks · latest Oct 28, 2026
Where ClearPoint Neuro Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CLPT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CLPT | BOATS | United States | USD |
Valuation
EV/sales 5.0× against a median of 3.4×: 8th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $226.2M USD
- P/E
- Loss
- EV/sales
- 5.0×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 8.1×
- Gross margin
- 61.4%
- Operating margin
- −70.6%
- Net margin
- −79.4%
- Debt to equity
- 1.9×
- Beta vs S&P 500
- 1.97
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ClearPoint Neuro Inc. · NASDAQ:CLPT | US$221.5M | US$226.2M | n/a | 5.0× | n/a | 8.1× | −79.4% | 1.9× | 1.97 |
| Profound Medical Corp · TSX:PRN | US$235.5M | US$206.6M | n/a | 8.8× | n/a | 5.5× | −137.5% | 0.1× | 1.19 |
| Jiangsu Nanfang Medical Co., Ltd. Class A · SSE:603880 | US$232.0M | US$233.5M | n/a | 2.8× | n/a | 10.4× | −18.9% | 0.3× | n/a |
| Jenscare Scientific Co. Ltd. Class H · HKEX:9877 | US$224.5M | US$168.3M | n/a | 12.7× | n/a | 2.0× | −299.4% | 0.1× | n/a |
| Utah Medical Products, Inc. · NASDAQ:UTMD | US$220.6M | US$135.6M | 20.7× | 3.9× | n/a | 1.8× | 30.5% | 0.0× | 0.31 |
| JVM Co., Ltd. · KRX:054950 | US$219.0M | US$106.5M | 9.6× | 0.8× | 3.4× | 1.2× | 17.4% | 0.0× | n/a |
| Bioteque Corporation · TPEX:4107 | US$217.6M | US$163.2M | 12.2× | 2.4× | 6.0× | 2.0× | 26.5% | 0.0× | n/a |
| Stille AB · OMXSTO:STIL | US$217.5M | US$200.8M | 23.1× | 2.9× | n/a | 2.8× | 13.5% | 0.0× | n/a |
| Touchstone International Medical Science Co. Ltd. Class A · SSE:688013 | US$216.1M | US$180.6M | 50.4× | 4.7× | n/a | 2.9× | 11.2% | 0.1× | n/a |
| Won Tech Co.,Ltd. · KRX:336570 | US$213.0M | US$147.6M | 7.2× | 1.2× | 4.4× | 1.7× | 23.9% | 0.2× | n/a |
| Spectral Medical Inc · TSX:EDT | US$210.9M | US$228.2M | n/a | 127× | n/a | n/a | n/a | n/a | 0.51 |
| Median of the others | US$218.3M | US$174.4M | 16.4× | 3.4× | 4.4× | 2.0× | 13.5% | 0.1× | 0.51 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.17 · 2 analysts
- Revenue, year to Dec 2026
- 48.5M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Joseph M. Burnett | President & CEO |
| Danilo D’Alessandro | Chief Financial Officer |
| Mazin Sabra | Chief Operating Officer |
| Chris Yelley | Vice President of Strategic Operations |
| Ernesto Salegio | Vice President, Segment Leader Translational & Pre-Clinical Research |
| Lyubomir Zagorchev | Vice President of Clinical Science & Applications |
| Mary McNamara-Cullinane | Vice President of Regulatory Affairs |
| Megan Faulkenberry | Vice President of Quality |
| Rob Korn | Senior Vice President of Sales & Business Development |
| Timothy Orr | Vice President of Software Development |
| Jeremy Stigall | Chief Business Officer |
| Paul S. Larson | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| R. John Fletcher | Chairman of the Board |
| B. Kristine Johnson | Director |
| Joseph M. Burnett | President & CEO |
| Linda M. Liau | Director |
| Lynnette C. Fallon | Director |
| Matthew Klein | Director |
| Timothy T. Richards | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| ClearPoint Neuro (NASDAQ:CLPT) Q3 2026 Earnings Call | Wed, Oct 28, 2026 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q2 2026 Earnings Call | Mon, Aug 03, 2026 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q1 2026 Earnings Call | Wed, May 13, 2026 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q4 2025 Earnings Call | Tue, Mar 17, 2026 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 5:00 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q1 2025 Earnings Call | Tue, May 13, 2025 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| ClearPoint Neuro (NASDAQ:CLPT) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 4:30 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 28, 2026 · After close | +1.2% |
| Q2 2026 | Aug 3, 2026 · After close | −16.3% |
| Q1 2026 | May 13, 2026 · After close | +4.8% |
| Q4 2025 | Mar 4, 2026 | +4.6% |
| Q3 2025 | Nov 6, 2025 · After close | −13.3% |
| Q2 2025 | Aug 12, 2025 · After close | +13.1% |
| Q1 2025 | May 13, 2025 · After close | −12.5% |
| Q4 2024 | Feb 26, 2025 | −15.0% |
| Q3 2024 | Nov 7, 2024 · After close | −13.2% |
| Q2 2024 | Aug 7, 2024 · After close | +40.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | +1.7% |
| Q4 2023 | Mar 12, 2024 · After close | +18.5% |
| Q3 2023 | Nov 9, 2023 · After close | −17.7% |
| Q2 2023 | Aug 8, 2023 · After close | −2.8% |
| Q1 2023 | May 11, 2023 · After close | −1.6% |
| Q4 2022 | Mar 1, 2023 · After close | −9.8% |
| Q3 2022 | Nov 8, 2022 · After close | −5.4% |
| Q2 2022 | Aug 9, 2022 · After close | +13.6% |
| Q1 2022 | May 11, 2022 · After close | +9.2% |
| Q4 2021 | Mar 1, 2022 · After close | +2.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 26 slides | Oct 28, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 26 slides | Aug 3, 2026 |
| Investor Presentation (May 2026) | Investor deck | 26 slides | May 13, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 8 slides | May 13, 2026 |
| Investor Presentation (March 2026) | Investor deck | 26 slides | Mar 17, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 26 slides | Mar 17, 2026 |
| Presentation (February 2026) | 10 slides | Feb 5, 2026 | |
| Investor Presentation (November 2025) | Investor deck | 31 slides | Nov 6, 2025 |
| Investor Presentation (August 2025) | Investor deck | 31 slides | Aug 12, 2025 |
| Investor Presentation (May 2025) | Investor deck | 31 slides | May 13, 2025 |
Show 50 decks
This page holds 50 of 61 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Notes Tranche closed: US$30M raised Buyers: Oberland Capital Management LLC (note financing of up to $105 Million, with $30.0 million funded at closing) Use of proceeds: General corporate purposes, which may include capital expenditures, working capital, and general and administrative expenses | May 12, 2025 |
| Registered direct offering of common stock Closed: US$3.5M raised · US$12.69 a share Buyers: Oberland Capital (275,808 shares for $3,500,003.52) Use of proceeds: General corporate purposes, which may include capital expenditures, working capital, and general and administrative expenses | May 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.0M | 31.4M | 24.0M | 20.6M | 16.3M | 12.8M | 11.2M | 7.35M | 7.38M | 5.75M |
| Cost of revenue | 14.3M | 12.3M | 10.3M | 7.02M | 5.18M | 3.71M | 3.94M | 2.43M | 2.90M | 2.64M |
| Gross profit | 22.7M | 19.1M | 13.6M | 13.5M | 11.1M | 9.12M | 7.28M | 4.92M | 4.48M | 3.11M |
| Research and development | 13.9M | 12.4M | 11.7M | 10.9M | 9.28M | 4.69M | 2.81M | 2.31M | 2.81M | 2.63M |
| Selling, general and administrative | 16.5M | 12.0M | 11.8M | 9.61M | 8.00M | 5.27M | 4.30M | 4.33M | 4.05M | 4.19M |
| Operating income | -24.2M | -19.7M | -22.4M | -16.3M | -13.4M | -6.22M | -4.59M | -5.25M | -6.34M | -7.49M |
| Depreciation and amortization | 814.0K | 980.0K | 626.0K | 244.0K | 159.0K | 334.0K | 144.0K | 109.4K | 116.5K | 155.7K |
| EBITDA | -23.4M | -18.8M | -21.8M | -16.1M | -13.2M | -5.89M | -4.45M | -5.14M | -6.22M | -7.33M |
| Interest expense | 2.39M | 518.0K | 81.0K | 973.0K | 1.44M | 955.0K | 980.4K | 872.9K | 1.05M | |
| Income before tax | -25.5M | -18.9M | ||||||||
| Income tax | 55.0K | 12.0K | 8.00K | 0 | 0 | 0 | ||||
| Net income | -25.5M | -18.9M | -22.1M | -16.4M | -14.4M | -6.78M | -5.54M | -6.16M | -7.17M | -8.07M |
| Earnings per share, basic | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.42 | -0.56 | -0.93 | -2.93 |
| Earnings per share, diluted | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.42 | -0.56 | -0.93 | -2.93 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 45.9M | 20.1M | 23.1M | 27.6M | 54.1M | 20.1M | 5.70M | 3.10M | 9.29M | 3.32M |
| Short-term investments | 0 | 9.87M | 0 | |||||||
| Receivables | 6.55M | 4.71M | 3.21M | 2.67M | 2.34M | 1.88M | 1.09M | 1.23M | 949.4K | 865.9K |
| Inventory | 8.36M | 6.86M | 7.91M | 9.30M | 4.94M | 3.24M | 3.24M | 2.11M | 2.31M | 1.77M |
| Current assets | 63.6M | 33.4M | 36.2M | 51.2M | 61.9M | 25.5M | 10.4M | 6.65M | 12.7M | 6.09M |
| Property, plant and equipment | 2.62M | 2.00M | 1.39M | 806.0K | 539.0K | 319.0K | 447.0K | 377.7K | 267.7K | 328.2K |
| Goodwill | 7.47M | 7.47M | ||||||||
| Total assets | 97.7M | 39.2M | 42.7M | 55.5M | 65.6M | 29.5M | 11.9M | 7.86M | 13.9M | 7.40M |
| Accounts payable | 1.26M | 1.34M | 393.0K | 272.0K | 427.0K | 300.0K | 966.0K | 500.9K | 759.4K | 1.55M |
| Current liabilities | 10.8M | 10.4M | 7.43M | 6.79M | 4.75M | 3.20M | 3.83M | 1.87M | 4.40M | 3.02M |
| Total debt | 49.1M | 9.95M | 9.89M | 9.84M | 21.3M | 2.07M | 3.48M | 4.92M | 4.49M | |
| Total liabilities | 69.7M | 13.8M | 21.5M | 18.6M | 16.8M | 27.1M | 7.34M | 6.35M | 8.07M | 8.16M |
| Shareholders' equity | 28.0M | 25.4M | 21.2M | 36.9M | 48.8M | 2.38M | 4.59M | 1.51M | 5.83M | -756.1K |
| Shares outstanding | 29.4M | 27.6M | 24.7M | 24.6M | 23.7M | 17.0M | 15.2M | 11.0M | 10.7M | 3.62M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.9M | -8.95M | -13.7M | -16.2M | -12.7M | -7.81M | -2.85M | -4.63M | -5.99M | -5.82M |
| Capital spending | -522.0K | -275.0K | -717.0K | -253.0K | -168.0K | -41.0K | -10.0K | -63.5K | -26.8K | -101.0K |
| Free cash flow | -24.4M | -9.22M | -14.4M | -16.4M | -12.9M | -7.85M | -2.86M | -4.69M | -6.02M | -5.92M |
| Cash from investing | 615.0K | -275.0K | 8.95M | -10.7M | -168.0K | -482.0K | -160.0K | -63.5K | -26.8K | -101.0K |
| Cash from financing | 50.2M | 6.19M | 296.0K | 409.0K | 46.9M | 22.7M | 5.61M | -1.49M | 12.0M | 3.83M |
| Change in cash | 26.9M | -3.04M | -4.47M | -26.5M | 34.0M | 14.4M | 2.60M | -6.19M | 5.97M | -2.09M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Material contract | SEC |
| S-3 · Registration statement | Nov 18, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 20, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 20, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Feb 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 9, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Feb 5, 2026 | Current report | SEC |
| D | Feb 5, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 26, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jan 23, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jan 22, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 20, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 14, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Material contract | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2025 | Acquisition or disposal | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 4, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 424B5 · Prospectus | May 12, 2025 | Offer document | SEC |
| 8-K · Current report | May 12, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from ClearPoint Neuro Inc.’s releases · as of Oct 21, 2026
- Common shares
- 32,054,268
- Fully diluted
- 32,054,268
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 32,054,268 | Oct 21, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 21, 2026 | 32,054,268 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Maria Sainz Other companies: Pulse Biosciences, Inc (Board Member · Since at least Jan 8, 2026); Hyperfine, Inc. (President and CEO · Since at least Dec 22, 2021); ATRION Corporation (Director · Aug 30, 2021 – May 24, 2022 · Past); Shockwave Medical Inc (Director · Jul 16, 2020 – May 31, 2024 · Past); Avanos Medical, Inc. (Director · Jan 2, 2019 – Jan 3, 2022 · Past); IRIDEX Corporation (Director · Apr 13, 2018 – Jul 23, 2019 · Past); Halyard Health Inc (Director · Feb 2, 2015 – May 3, 2018 · Past); The Spectranetics Corp (Director · Nov 1, 2010 – Aug 9, 2017 · Past); Orthofix Medical Inc. (Director · Jun 19, 2008 – Jun 8, 2020 · Past); Guidant Corp (President, Cardiac Surgery · Mar 31, 2006 – Apr 21, 2006 · Past) | Director · Jan 1, 2014 – Mar 30, 2018 · Past |
| B. Kristine Johnson Other companies: AtriCure, Inc. (Director · Since at least Mar 21, 2017); Paragon 28 Inc (Director · Dec 1, 2021 – Apr 21, 2025 · Past); The Spectranetics Corp (Director · May 31, 2012 – Aug 9, 2017 · Past); Piper Sandler Companies (Director · May 5, 2010 – Dec 13, 2019 · Past) | Director · Since at least Sep 1, 2019 |
| R. John Fletcher Other companies: KORU Medical Systems, Inc. (Director · Since at least May 7, 2019); OptiNose (Director · Apr 26, 2022 – May 21, 2025 · Past); Vyant Bio Inc (Director · Mar 30, 2021 – Jan 17, 2023 · Past); Axcelis Technologies, Inc. (Director · May 15, 2019 – Feb 17, 2021 · Past) | Director · Since at least Mar 29, 2019 |
| Marcio Souza Other companies: Praxis Precision Medicines, Inc. (President & Chief Executive Officer · Since at least Oct 15, 2020); Spyre Therapeutics, Inc. (Director · Jun 18, 2021 – Aug 25, 2022 · Past); PTC Therapeutics, Inc. (Chief Operating Officer · May 31, 2017 – Feb 10, 2020 · Past) | Director · May 17, 2019 – May 17, 2019 · Past |
| Michael Pietrangelo Other companies: Universal Insurance Holdings Inc (Director · Since at least Mar 26, 2010); Medicis Pharmaceutical Corp (Director · Sep 29, 2006 – Nov 30, 2012 · Past) | Director · Feb 27, 2012 – Jun 30, 2014 · Past |
| Charles E Koob Other companies: MiMedx Group, Inc (Director · May 18, 2016 – Oct 2, 2020 · Past) | Director · Jun 30, 2015 – Oct 4, 2017 · Past |
| Lynnette C. Fallon Other companies: Axcelis Technologies, Inc. (EXECUTIVE VP, HR/LEGAL · May 15, 2019 – Jan 3, 2025 · Past) | Director · Since at least Jul 15, 2021 |
| Matthew B. Klein Other companies: PTC Therapeutics, Inc. (Chief Executive Officer · Since at least Apr 21, 2026) | Director · Since at least May 19, 2026 |
| Philip A Pizzo Other companies: Global Blood Therapeutics Inc (Director · Sep 23, 2015 – Oct 5, 2022 · Past) | Director · Jun 30, 2015 – Oct 4, 2017 · Past |
| Bruce C Conway | Director · Feb 27, 2012 – Mar 22, 2013 · Past |
All 33 people
| Person | Seat |
|---|---|
| Carol J Barbre | VP Product Management · Feb 27, 2012 – Apr 13, 2012 · Past |
| Chris Yelley | Vice President of Strategic Operations · Since at least Nov 5, 2026 |
| Danilo D'Alessandro | Chief Financial Officer · Since at least Sep 29, 2020 |
| David W Carlson | Chief Financial Officer · Feb 27, 2012 – Nov 5, 2013 · Past |
| Ernesto Salegio | Vice President, Segment Leader Translational & Pre-Clinical Research · Since at least Nov 5, 2026 |
| Francis P Grillo | CHIEF EXECUTIVE OFFICER, Director · Oct 4, 2017 – Nov 7, 2017 · Past |
| Harold A Hurwitz | Chief Financial Officer · Aug 15, 2019 – Jul 9, 2020 · Past |
| Jacqueline Keller | Vice President of Marketing · Nov 13, 2024 – Nov 5, 2026 · Past |
| James K Malernee Jr | Director · Feb 27, 2012 – Dec 31, 2013 · Past |
| Jeremy Stigall | Chief Business Officer · Since at least May 13, 2022 |
| Joseph M. Burnett | CEO and President, Director · Since at least Nov 7, 2017 |
| Kimble L Jenkins | Director · Feb 27, 2012 – Sep 30, 2020 · Past |
| Linda M. Liau | Director · Since at least Nov 2, 2021 |
| Lyubomir Zagorchev | Vice President of Clinical Science & Applications · Since at least Nov 5, 2026 |
| Mary McNamara-Cullinane | Vice President of Regulatory Affairs · Since at least Apr 20, 2026 |
| Mazin Sabra | Chief Operating Officer · Since at least Jan 22, 2026 |
| Megan Faulkenberry | Vice President of Quality · Since at least Feb 12, 2025 |
| Michael J Ryan | Director · Jun 14, 2013 – Mar 31, 2015 · Past |
| Pascal E R Girin | Director · Since at least Sep 3, 2014 |
| Paul Larson | Chief Medical Officer · Since at least Sep 25, 2025 |
| Rob Korn | Senior Vice President of Sales & Business Development · Since at least Nov 5, 2026 |
| Timothy Orr | Vice President of Software Development · Since at least Nov 5, 2026 |
| Timothy T. Richards | Director · Since at least Apr 1, 2025 |
Log in to ask 6ix AI your own questions about ClearPoint Neuro Inc.